Acelrx Pharmaceuticals Inc ACRX

NAS: ACRX | ISIN: US00444T1007   12/03/2024
1,128 USD (+2,52%)
(+2,52%)   12/03/2024

9 januari 2024 · AcelRx Announces Rebranding With Name Change to Talphera, Inc. · Persbericht

12 december 2023 · AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States · Persbericht

8 november 2023 · AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

7 november 2023 · AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study · Persbericht

26 oktober 2023 · AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 · Persbericht

3 oktober 2023 · AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study · Persbericht

6 september 2023 · AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference · Persbericht

10 augustus 2023 · AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

27 juli 2023 · AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 · Persbericht

21 juli 2023 · AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules · Persbericht

18 juli 2023 · AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules · Persbericht

10 mei 2023 · AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

27 april 2023 · AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 · Persbericht

5 april 2023 · AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals · Persbericht

30 maart 2023 · AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

21 maart 2023 · AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 · Persbericht

14 maart 2023 · AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals · Persbericht

1 maart 2023 · AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures · Persbericht

27 december 2022 · AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock · Persbericht

8 december 2022 · AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine · Persbericht

Mijn selecties